|
Neuer Investor mit massiven Aktienkauf von 1.3 Million anteilen 5,5% wenn das mal kein gutes Zeichen ist . http://ih.advfn.com/p.php?pid=nmona&article=74443449 Marktkap $95 M / Cash $60 M / 5x Phase 3 Studien in verschiedene indikationen = Für ein Biotech SEHR attraktiv Marktkap: $93 M Cash: $60 M (inkl $10M Kredit) reicht bis mitte 2019 Kurs: $4.10 Aktienanzahl: 22.9 M Anticipated Near-Term Clinical Milestones Clinical Trial Readouts: -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017) -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017) -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018) AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.) AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.) AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.) AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.) AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.) |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | Biohero (28.04.17 12:17:01) |
| Beitrag: | 49 von 268 (ID:54828181) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |